European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - lipoteichoic acid from biofilm adhesion component of streptococcus uberis, strain 5616 - immunologicals for bovidae - cattle - for active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by streptococcus uberis, to reduce the somatic cell count in streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by streptococcus uberis intramammary infections.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

laboratorios hipra s.a. - streptococcus uberis antigen - unknown - streptococcus uberis antigen vaccine-antigen active 0.0 - active constituent

New Zealand - English - Ministry for Primary Industries

hipra new zealand limited - biofilm adhesion component of streptococcus uberis, strain 5616 - biofilm adhesion component of streptococcus uberis, strain 5616 0 vaccine - vaccine

United Kingdom - English - VMD (Veterinary Medicines Directorate)

laboratorios hipra sa - biofilm adhesion component (bac) of streptococcus uberis - emulsion for injection - inactivated bacterial vaccine - cattle

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - glibenclamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide, quantity: 5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; pregelatinised maize starch; lactose monohydrate; purified talc; maize starch - daonil and semi-daonil are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2) whose hyperglycaemia cannot be controlled by diet alone. because of its broad and predictable action, daonil and semi-daonil are often suitable for the management of patients who have failed to respond to other oral antidiabetics.,in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment programme fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea should be considered. use of daonil and semi-daonil must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - ascorbic acid (vitamin c); betacarotene; calcium hydrogen phosphate; choline bitartrate; cholecalciferol; cyanocobalamin; ferrous fumarate; folic acid; inositol; magnesium phosphate; manganese sulphate monohydrate; nicotinamide; potassium sulfate; pyridoxine hydrochloride; riboflavin; sodium molybdate dihydrate; thiamine hydrochloride; zinc sulphate; copper sulphate; d-biotin; calcium d-pantothenate; dl-alpha tocopheryl acetate; lecithin soya bean; d-panthenol -